Edesa Biotech (EDSA) Intangibles (2013 - 2026)
Edesa Biotech (EDSA) posted Intangibles of $2.0 million for Q4 2025, down 1.28% sequentially from $2.0 million in Q3 2025, and down 4.93% YoY from $2.1 million in Q4 2024.
Edesa Biotech (EDSA) Intangibles (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Intangibles for 7 years, with the latest figure at $2.0 million in Q4 2025.
- Quarterly Intangibles fell 4.93% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.0 million (down 4.93% YoY) and the FY2025 annual result came in at $2.0 million, down 4.87% from the prior year.
- Intangibles fell to $2.0 million in Q4 2025 per EDSA's latest filing, from $2.0 million in the prior quarter.
- Over five years, Intangibles peaked at $2529.5 billion in Q2 2021 and troughed at $2.0 million in Q4 2025.
- A 5-year average of $126.5 billion and a median of $2.3 million in 2022 frame the typical range for Intangibles.
- The sharpest annual moves came in 2021 and 2022: Intangibles surged 100823152.6% in 2021, then plunged 100.0% in 2022.
- Over 5 years, Intangibles stood at $2.4 million in 2021, then dropped by 4.29% to $2.3 million in 2022, then gained by 12.13% to $2.5 million in 2023, then declined by 18.82% to $2.1 million in 2024, then fell by 4.93% to $2.0 million in 2025.
- According to Business Quant data, Intangibles over the past three periods registered $2.0 million, $2.0 million, and $2.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - | 1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.90 Mn |
| Dec 31, 2025 | 1.95 Mn |
| Sep 30, 2025 | 1.98 Mn |
| Jun 30, 2025 | 2.00 Mn |
| Mar 31, 2025 | 2.03 Mn |
| Dec 31, 2024 | 2.05 Mn |
| Sep 30, 2024 | 2.08 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Dec 31, 2023 | 2.53 Mn |
| Sep 30, 2023 | 2.18 Mn |
| Jun 30, 2023 | 2.53 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Dec 31, 2022 | 2.26 Mn |
| Sep 30, 2022 | 2.28 Mn |
| Jun 30, 2022 | 2.31 Mn |
| Mar 31, 2022 | 2.33 Mn |
| Dec 31, 2021 | 2.36 Mn |
| Sep 30, 2021 | 2.38 Mn |
| Jun 30, 2021 | 2,529.48 Bn |